JP2022543780A5 - - Google Patents
Info
- Publication number
- JP2022543780A5 JP2022543780A5 JP2022506485A JP2022506485A JP2022543780A5 JP 2022543780 A5 JP2022543780 A5 JP 2022543780A5 JP 2022506485 A JP2022506485 A JP 2022506485A JP 2022506485 A JP2022506485 A JP 2022506485A JP 2022543780 A5 JP2022543780 A5 JP 2022543780A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- use according
- subject
- dose
- paclitaxel
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962881894P | 2019-08-01 | 2019-08-01 | |
| US62/881,894 | 2019-08-01 | ||
| PCT/US2020/031181 WO2020223702A1 (en) | 2019-05-01 | 2020-05-01 | Anti-galectin-9 antibodies and uses thereof |
| USPCT/US2020/031181 | 2020-05-01 | ||
| PCT/US2020/044777 WO2021022256A1 (en) | 2019-08-01 | 2020-08-03 | Combined cancer therapy of anti-galectin-9 antibodies and chemotherapeutics |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2022543780A JP2022543780A (ja) | 2022-10-14 |
| JP2022543780A5 true JP2022543780A5 (enExample) | 2023-08-10 |
| JP7703513B2 JP7703513B2 (ja) | 2025-07-07 |
Family
ID=74229293
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2022506485A Active JP7703513B2 (ja) | 2019-08-01 | 2020-08-03 | 抗ガレクチン９抗体と化学療法剤の組合せがん治療 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20220332832A1 (enExample) |
| EP (1) | EP4007640A4 (enExample) |
| JP (1) | JP7703513B2 (enExample) |
| CN (1) | CN114502241B (enExample) |
| AU (1) | AU2020319899B2 (enExample) |
| CA (1) | CA3149324A1 (enExample) |
| WO (1) | WO2021022256A1 (enExample) |
Families Citing this family (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG11202003652QA (en) | 2017-10-27 | 2020-05-28 | Univ New York | Anti-galectin-9 antibodies and uses thereof |
| AU2020266677A1 (en) * | 2019-05-01 | 2022-01-06 | New York University | Anti-Galectin-9 antibodies and uses thereof |
| JP2024519450A (ja) * | 2021-04-30 | 2024-05-14 | ピュアテック・エル・ワイ・ティ・インコーポレイテッド | 抗ガレクチン－９抗体及びその治療的使用 |
| JP2024519449A (ja) * | 2021-04-30 | 2024-05-14 | ピュアテック・エル・ワイ・ティ・インコーポレイテッド | がん治療における使用のための抗ガレクチン－９抗体と化学療法剤との併用 |
| CN113624965B (zh) * | 2021-08-05 | 2024-02-09 | 中国人民解放军军事科学院军事医学研究院 | N蛋白特异性IgG4在甄别新型冠状病毒感染者和疫苗接种者中的应用 |
| AU2022355201A1 (en) * | 2021-10-01 | 2024-04-04 | Beigene Switzerland Gmbh | Anti-galectin-9 antibodies and therapeutic uses thereof |
| CN119286974A (zh) * | 2024-12-12 | 2025-01-10 | 南方医科大学南方医院 | 一种晚期结直肠癌靶向治疗预测模型的构建系统 |
| CN120585880B (zh) * | 2025-08-07 | 2025-12-09 | 四川大学华西医院 | 一种用于预防和/或治疗前列腺癌的联合用药物，其用途及药物组合物 |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9511046B2 (en) * | 2013-01-11 | 2016-12-06 | Abraxis Bioscience, Llc | Methods of treating pancreatic cancer |
| FR3021970B1 (fr) * | 2014-06-06 | 2018-01-26 | Universite Sciences Technologies Lille | Anticorps dirige contre la galectine 9 et inhibiteur de l'activite suppressive des lymphocytes t regulateurs |
| WO2016008005A1 (en) * | 2014-07-14 | 2016-01-21 | The Council Of The Queensland Institute Of Medical Research | Galectin immunotherapy |
| KR102124286B1 (ko) * | 2016-09-07 | 2020-06-18 | 삭신 라이프사이언스 피브이티 엘티디 | Vegf에 대한 합성 항체 및 이들의 용도 |
| CA3073531A1 (en) * | 2017-09-13 | 2019-03-21 | Five Prime Therapeutics, Inc. | Combination anti-csf1r and anti-pd-1 antibody combination therapy for pancreatic cancer |
| SG11202003652QA (en) * | 2017-10-27 | 2020-05-28 | Univ New York | Anti-galectin-9 antibodies and uses thereof |
-
2020
- 2020-08-03 JP JP2022506485A patent/JP7703513B2/ja active Active
- 2020-08-03 CA CA3149324A patent/CA3149324A1/en active Pending
- 2020-08-03 EP EP20846431.3A patent/EP4007640A4/en active Pending
- 2020-08-03 US US17/631,378 patent/US20220332832A1/en active Pending
- 2020-08-03 CN CN202080068359.6A patent/CN114502241B/zh active Active
- 2020-08-03 WO PCT/US2020/044777 patent/WO2021022256A1/en not_active Ceased
- 2020-08-03 AU AU2020319899A patent/AU2020319899B2/en active Active
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022531408A5 (enExample) | ||
| Al-Samkari | Optimal management of chemotherapy-induced thrombocytopenia with thrombopoietin receptor agonists | |
| JP2024516217A5 (enExample) | ||
| JP2024519449A5 (enExample) | ||
| WO2023134706A1 (zh) | 抗trop-2抗体偶联药物和其他治疗剂的组合用途 | |
| WO2022270524A1 (ja) | 癌の治療及び／又は予防のための医薬品 | |
| US11648310B2 (en) | Combination of anti-FGFR4-antibody and bile acid sequestrant | |
| JP2021511344A5 (enExample) | ||
| JP2024519450A5 (enExample) | ||
| JP2024536383A5 (enExample) | ||
| JP2023551980A5 (enExample) | ||
| JP2024527974A5 (enExample) | ||
| AU2024344603A1 (en) | Use of anti-b7h3 antibody-drug conjugate in preparation of drug for treating nasopharyngeal carcinoma and/or lymphoepithelioma-like carcinoma | |
| CN119055767A (zh) | 包含抗her2双特异性抗体的联合治疗药物及其用途 | |
| KR20260025124A (ko) | 클라우딘 18.2를 표적으로 하는 항체-약물 접합체를 이용한 고형 종양의 치료 방법 | |
| JP7556468B2 (ja) | Ｃｄ４７阻害物質、免疫チェックポイント阻害物質および標準療法の併用によるがん治療法 | |
| CN120752053A (zh) | 含抗tim-3抗体的药物组合 | |
| CN119789867A (zh) | 结合tim-3的抗体与结合pd-1的抗体的药物组合 | |
| CN111065412B (zh) | Pd-1抗体和阿帕替尼联合治疗三阴性乳腺癌的用途 | |
| JP2022531894A5 (enExample) | ||
| JP2024536201A5 (enExample) | ||
| CN112543637B (zh) | 伊立替康联合免疫检查点抑制剂和5-fu在制备治疗肿瘤疾病的药物中的用途 | |
| TW201922292A (zh) | 免疫治療劑、核苷類抗代謝物和鉑類聯合在製備治療腫瘤的藥物中的用途 | |
| JP2025540063A (ja) | 抗体－薬物コンジュゲートおよびｄｎｍｔ阻害剤の併用 | |
| HK40122430A (zh) | 抗b7h3抗体-药物偶联物治疗癌症的方法 |